JAC Advance Access published online on January 13, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh530
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Rega Institute for Medical Research, K. U. Leuven, B-3000 Leuven, Belgium
* To whom correspondence should be addressed. Pyridine N-oxide derivatives represent a new class of anti-HIV compounds, for which some members exclusively act through inhibition of HIV-1 reverse transcriptase and thus characteristically behave as non-nucleoside reverse transcriptase inhibitors. Other members act, additionally or alternatively, at a post-integrational event in the replication cycle of HIV, that is, at the level of HIV gene expression. Repeated administration of one of the prototype compounds (JPL-32) to DBA/2 and hu-PBMC-SCID mice demonstrated, in the absence of any acute toxicity, protective activity against HIV-induced destruction of CD4 human T lymphocytes.
Leading article
Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action
Jan Balzarini, E-mail: jan.balzarini{at}rega.kuleuven.ac.be
![]()
Abstract
B; reverse transcriptase; NNRTI;transcription inhibitors; HIV chemotherapy.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. Balzarini, E. Keyaerts, L. Vijgen, F. Vandermeer, M. Stevens, E. De Clercq, H. Egberink, and M. Van Ranst Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture J. Antimicrob. Chemother., March 1, 2006; 57(3): 472 - 481. [Abstract] [Full Text] [PDF] |
||||
